IDEXX Laboratories Announces Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
IDEXX Labs (IDXX) Tops Q3 EPS by 8c; Raises FY18 EPS Outlook, Maintains FY18 Revenue Guidance, Offers Prelim. FY19 EPS/Revenue Views
November 1, 2018 6:41 AM EDT(Updated - November 1, 2018 6:56 AM EDT)
(Update corrects consensus revenue figure)
IDEXX Labs (NASDAQ: IDXX) reported Q3 EPS of $1.05, $0.08 better than the analyst estimate of $0.97. Revenue for the quarter came in at $545.45 million versus the consensus estimate of $545.49 million.
Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organicDelivers EPS of $1.05, a 33% increase year-over-year on a reported basis or 39% on a comparable constant currency basisRefines 2018 reported revenue guidance to $2,205 billion - $2,215... More


